U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07136558) titled 'Evaluation of ICP-B794 in Patients With Advanced Solid Tumors' on Aug. 05.
Brief Summary: An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients with Advanced Solid Tumors
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: ICP-B794
Intravenous administration once every 3 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....